Zhiyong Ma

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial

Yi‐Long Wu, Shun Lü, Ying Cheng et al. · Journal of Thoracic Oncology · 2019 · 347 citations

Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial

Shun Lü, Jie Wang, Yan Yu et al. · Journal of Thoracic Oncology · 2021 · 264 citations · Full text

Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study

Qing Zhou, Chong‐Rui Xu, Ying Cheng et al. · Cancer Cell · 2021 · 220 citations

Advanced Nsclc, Novel Therapy, Multicenter Phase 3 +9

Early detection of lung cancer by using an autoantibody panel in Chinese population

Shengxiang Ren, Shucai Zhang, Tao Jiang et al. · OncoImmunology · 2017 · 200 citations · Full text

Epidemiology Of Cancer, Immunology, 7-Aabs Panel +16

Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy

Caicun Zhou, Yina Wang, Jun Zhao et al. · Clinical Cancer Research · 2021 · 126 citations · Full text